Antonella Giannantoni

Prof. Antonella Giannantoni


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in European Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
EMEttore Mearini
Ettore Mearini
MZMichele Del Zingaro
Michele Del Zingaro
MPMassimo Porena
Massimo Porena

1 March 2008 in Journal of Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
MPMassimo Porena
Massimo Porena
ECElisabetta Costantini
Elisabetta Costantini
AZAlessandro Zucchi
Alessandro Zucchi
LMLuigi Mearini
Luigi Mearini
EMEttore Mearini
Ettore Mearini
We evaluated the 1-year efficacy and tolerability of botulinum A toxin intravesically injected in patients with painful bladder symptoms associated with increased urinary frequency, refractory to conventional treatments. Three men and 12 women were prospectively included in the study. Under short general anesthesia the patients were given injections of 200 U commercially available botulinum A toxin diluted in 20 ml 0.9% NaCl. Injections were performed submucosally in the bladder trigone and lateral walls under cystoscopic guidance. A voiding chart and the visual analog scale for pain were used, and urodynamics were performed before treatment, and 1, 3, 5 and 12 months later. Overall 13 patients (86.6%) reported subjective improvement at the 1 and 3-month followups. The mean visual analog scale score, and daytime and nighttime urinary frequency were significantly decreased (p <0.05, <0.01 and <0.05, respectively). At the 5-month followup the beneficial effects persisted in 26.6% of cases but increased daytime and nighttime urinary frequency, and an increased visual analog scale score were observed compared to baseline. At 12 months after treatment pain recurred in all patients. Nine patients complained of dysuria 1 month after treatment. Dysuria persisted in 4 cases at the 3-month followup and in 2 at the 5-month followup. Intravesically injected botulinum toxin A is effective for short-term management of refractory painful bladder syndrome. The beneficial effects decreased progressively within a few months after treatment. Thus, repeat injections of the neurotoxin are required for efficacious treatment in patients with the disease.

1 October 2009 in Journal of Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
ARAroldo Rossi
Aroldo Rossi
EMEttore Mearini
Ettore Mearini
MZMichele Del Zingaro
Michele Del Zingaro
MPMassimo Porena
Massimo Porena
ABAlfredo Berardelli
Alfredo Berardelli
Urinary disturbances are common in patients with Parkinson's disease and multiple system atrophy. We investigated the effectiveness and safety of botulinum toxin type A injected into the detrusor muscle in patients with Parkinson's disease and multiple system atrophy who had refractory overactive bladder symptoms and detrusor overactivity. All participants underwent clinical and urodynamic assessment, and completed a quality of life questionnaire before botulinum toxin type A treatment, and 1 and 3 months thereafter. Four patients with Parkinson's disease and 2 with multiple system atrophy were enrolled in the study. All patients received 200 U botulinum toxin type A injected into the detrusor muscle at 20 sites under cystoscopic guidance at a single session on an inpatient basis. Outcome measures were clinical assessment (a voiding diary including daytime and nighttime urinary frequency, and episodes of urgency and urge urinary incontinence), urodynamic assessment (including first volume and maximum pressure of uninhibited detrusor contractions, and maximum cystometric capacity) and pressure flow studies. One and 3 months after botulinum toxin type A injection all patients reported that daytime and nighttime urinary frequency had decreased and quality of life scores improved. No patients had further episodes of urgency and urge urinary incontinence during the 5-month followup. Urodynamics showed improvement in all urinary function variables tested. No systemic side effects were recorded during or after treatment. In all patients post-void urinary residual volume increased and intermittent catheterization was required only in those with multiple system atrophy. The new beneficial effect that we report in a small study sample encourages larger trials to confirm botulinum toxin type A injection into the detrusor muscle as an effective and safe treatment for refractory overactive bladder symptoms and detrusor overactivity related to Parkinson's disease and multiple system atrophy.

1 January 2012 in European Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
VBVittorio Bini
Vittorio Bini
RDRoger Dmochowski
Roger Dmochowski
PHPhilip Hanno
Philip Hanno
JNJ. Curtis Nickel
J. Curtis Nickel
JWJean Jacques Wyndaele
Jean Jacques Wyndaele

1 September 2011 in Journal of Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
ACAntonella Conte
Antonella Conte
SPSilvia Proietti
Silvia Proietti
SGSilvia Giovannozzi
Silvia Giovannozzi
ARAroldo Rossi
Aroldo Rossi
ABAlfredo Berardelli
Alfredo Berardelli
In this 6-month followup study we investigated the effect of intradetrusor injection of 100 U botulinum toxin type A in patients with Parkinson's disease and refractory detrusor overactivity. Eight patients with Parkinson's disease and detrusor overactivity refractory to anticholinergics were injected with 100 U botulinum toxin type A. Daytime and nighttime urinary frequency, and urinary incontinence episodes were recorded. Patients also completed a standardized quality of life questionnaire on incontinence and a visual analog scale on the impact of bladder problems on daily life activities, and underwent urodynamic assessment, including pressure flow studies. Clinical and urodynamic assessment was performed before, and 1, 3 and 6 months after injection. In all patients 100 U botulinum toxin type A induced decreased daytime and nighttime urinary frequency, a decreased number of urinary incontinence episodes, increased quality of life scores and, as shown by increased maximum cystometric capacity, improved urodynamic findings. In 2 patients with Parkinson's disease post-void residual urine volume developed. Intradetrusor injection of 100 U botulinum toxin type A induced clinical and urodynamic improvement in overactive bladder symptoms that lasted at least 6 months in patients with Parkinson's disease.

1 February 2014 in Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
MPMassimo Porena
Massimo Porena
MGMarilena Gubbiotti
Marilena Gubbiotti
SMStefania Maddonni
Stefania Maddonni
SSSavino M. Di Stasi
Savino M. Di Stasi